ClinicalTrials.gg
CompletedNCT00866970Updated Jul 9, 2020

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

A Phase 2 interventional study of ALD518 and ALD518 in NSCLC, Fatigue and Cachexia, sponsored by CSL Behring. Completed at 43 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-09.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Fatigue with a site in India — 3 open to participants now, 3 under way, 3 of them phase 3. Fatigue · India.

Enrollment
7th of 11
124 · median 128
Started
2008
the only one that year
Phase 2
Only one
of the 12
Registered
1st of 12
by date
Lead sponsor
1 of 12
CSL Behring

Among the 12 studies in Fatigue with a site in India, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2008, is the only one in phase 2, and was the 1st registered.

Fatigue

2,232 studies on the registry are indexed under Fatigue; 427 are open to participants now.

Browse Fatigue studies →

Open to participants now

3 of the 12 studies in Fatigue with a site in India are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 239 Fatigue studies recruiting now, 111 (46%) set no upper age limit and 98 (41%) stop at 75 or younger; 23 take children under 18; 73 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Fatigue with a site in India, or all of them as a file.
02

Study summary

The purpose of this study is to asses the safety and efficacy of ALD518 in patients with Non-Small Cell Lung Cancer-Related Fatigue and cachexia (weight-loss).

Read the detailed description

This is a phase II, double-blind, randomized, placebo-controlled study of ALD518 in patients with NSCLC related fatigue and cachexia.

It is estimated that a total of 120 patients will be randomized to ALD518 80 mg, 160 mg, 320 mg, or placebo in a 1:1:1:1 ratio.

A total of eight visits (excluding the Screening visit) will take place over a period of 24 weeks: Day 1, Weeks 2, 4, 8, 12, 16, 20, and 24.

Enrolled patients will be screened within a 4 week period (Day 35 to 7). Randomization to treatment will be within a 12 day period (Day 14 to 3), before initial dosing on Day 1.

Patients will receive treatment eight weeks apart (on Day 1, and Weeks 8 and 16). All patients will remain at the clinic for at least 4 hours from the time the infusion is started. Follow-up visits will occur four and eight weeks after the last dose of study drug, at Weeks 20 and 24, respectively.

03

Conditions studied

  • NSCLC
  • Fatigue
  • Cachexia

Keywords

  • Lung Cancer
  • Fatigue
  • Cachexia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of NSCLC incurable by other treatments including surgery
  • A ≥5 % loss of body weight in the preceding 3 months
  • A C-reactive protein (CRP) concentration ≥ 10 mg/L
  • of at least 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Treatment with chemotherapy, large-field radiotherapy, or surgery for treatment of cancer in the past 30 days
  • /ALT ≥ 3 x at screening
  • \< 8 g/dL at Screening
  • History of or active diagnosis of Tuberculosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    1

    ALD518

    Biological: ALD518

  • Experimental
    2

    ALD518

    Biological: ALD518

  • Experimental
    3

    ALD518

    Biological: ALD518

  • Placebo comparator
    4

    No ALD518

    Biological: Infusion of 0.9% Saline without ALD518

Interventions

  • BiologicalALD518

    ALD518 80 mg on Day 1, Week 8 and Week 16

  • BiologicalALD518

    ALD518 160 mg IV on Day 1, Week 8 and Week 16

  • BiologicalALD518

    ALD518 360 mg IV on Day 1, Week 8, and Week 16

  • BiologicalInfusion of 0.9% Saline without ALD518

    Infusion of 0.9% Saline without addition of ALD518

06

What researchers measure

Primary outcomes

  1. Change in Safety parameters.

    Time frame: 20 weeks

Secondary outcomes

  1. Time to symptomatic progressions at Weeks 12 and 24

    Time frame: 24 weeks

07

Study locations

43 sites
  • Rivercity Hospital Research Centre
    Auchenflower, Queensland 4066, Australia
  • Australian Clinical Research Organisation
    Kippa Ring, Queensland 4021, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Palliative Care Launceston General Hospital
    Launceston, Tasmania 7250, Australia
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Atlantic Health Sciences Corporation
    Saint John, New Brunswick E2l 4L2, Canada
  • McGill University, Department of Oncology
    Montreal, Quebec H2W 1S6, Canada
  • A. Gvamichava National Cancer Centre
    Tbilisi, 0177, Georgia
  • Union Cancer Prevention Centre
    Tbilisi, 0177, Georgia
  • Medulla Chemotherapy and Immunotherapy Clinic
    Tbilisi, 0186, Georgia
  • Indira Gandhi Institute of Medical Sciences
    Patna, Bihar, India
  • Dr. Kamakshi Memorial Hospital
    Pallikaranai, Chennai 600100, India
  • GKNM Hospital
    Pappanaickenpalayam, Coimbatore 641037, India
  • Curie Manavata Cancer Centre
    Nasik, Maharashtra 422 304, India
  • Kidwai Memorial Institute of Oncology
    Bangalore, 560029, India
  • Kailash Cancer Hospital and Research Centre
    Gujarat, 391760, India
  • IndoAmerican Cancer Institute & Research Center
    Hyderabad, 500034, India
  • SEAROC Cancer Centre
    Jaipur, 302013, India
  • Orchid Nursing Home
    Kolkata, 700 054, India
  • Tata Memorial Hospital
    Mumbai, 400 012, India
  • Shatabdi Hospital
    Mumbai, India
  • Mahavir Cancer Sansthan
    Patna, 801505, India
  • Jehangir Clinical Development Centre Pvt. Ltd.
    Pune, 411 001, India
  • P3 Research LTD
    Tauranga, 31-40, New Zealand
  • Oddzial Chorob Pluc i Leczenia Raka Pluc
    Bydgoszcz, 85-326, Poland
  • Oddzial Chemioterapii Szpital Morski
    Gdynia, 81-519, Poland
  • II Oddzia Chorob Pluc z Pododdzialem Chemioterapii
    Krakow, 31-202, Poland
  • Oddzial II Chemioterapii Specjalistyczny Szpital
    Szczecin, 70-891, Poland
  • Professor Dr. Al Trestioreanu Institute
    Bucharest, 022328, Romania
  • Professor Dr. I Chiricuta Institute of Oncology and Radiotherapy
    Cluj-Napoca, 400015, Romania
  • Oradea Clinical County Hospital Medical Oncology Department
    Oradea, 410032, Romania
  • County Hospital Sibiu Medical Oncology Department
    Sibiu, 550245, Romania
  • Territorial Clinical Oncology Dispensary
    Krasnodar, Krasnodar Territory 350040, Russian Federation
  • Republic Oncology Dispensary
    Ufa, Republic Of Bashkortostan 450054, Russian Federation
  • Stavropol Territorial Clinical
    Pyatigorsk, Stavropol Territory 357500, Russian Federation
  • City Clinical Hospital No. 1
    Novosibirsk, 630047, Russian Federation
  • Saint-Petersburg State Medical University, I.P. Pavlov
    Saint-Petersburg, 197022, Russian Federation
  • St. Petersburg City Oncology Dispensary
    Saint-Petersburg, 198255, Russian Federation
  • Yaroslavl Regional clinical Oncology Hospital
    Yaroslavl, 150054, Russian Federation
  • Institute of Lung Diseases and TB
    Belgrade, 11 000, Serbia
  • Clinical Hospital Center Bezanijska Kosa
    Belgrade, 11080, Serbia
  • Clinical Centre Kragujevac
    Kragujevac, 34000, Serbia
  • Institute for Pulmonary diseases of Vojvodina
    Sremska, 21 104, Serbia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Aug 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2009
First posted
Mar 23, 2009
Start
Sep 2008
Primary completionActual
Aug 2009
CompletionActual
Dec 2009
Last update
Jul 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00866970
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Mar 23, 2009
Start date
Sep 2008
Primary completion
Aug 2009
Completion
Dec 2009
Last update
Jul 9, 2020

Study contacts

Jeffrey TL Smith, MD FRCP
study director · Alder Biopharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clazakizumab

Start the discussion